Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Oct 14, 2009; 15(38): 4753-4762
Published online Oct 14, 2009. doi: 10.3748/wjg.15.4753
Published online Oct 14, 2009. doi: 10.3748/wjg.15.4753
Figure 4 Emodin inhibits expression of protein and mRNA levels of Smad4 in liver tissues in the rat model.
A piece of liver tissue was collected from each treated rat. A: Smad4 proteins in liver tissue were stained by IHC. Representative views from each group (n = 6 per group) are presented (original magnification, × 400). Arrows indicate an area positively labeled with Smad4; B: Semi-quantification of Smad4 staining. Values are expressed as mean ± SD, n = 6 per group. aP < 0.05 vs CCl4 group; C: Real-time PCR analyses of the mRNA levels of Smad4. Values are presented as means ± SD, n = 5 per group. GAPDH was used as an invariant internal control for calculating mRNA -fold changes; D, E: Western blotting analyses of the protein abundance of Smad4. GAPDH was used as an invariant control for equal loading. aP < 0.05 vs CCl4 group.
-
Citation: Dong MX, Jia Y, Zhang YB, Li CC, Geng YT, Zhou L, Li XY, Liu JC, Niu YC. Emodin protects rat liver from CCl4-induced fibrogenesis
via inhibition of hepatic stellate cells activation. World J Gastroenterol 2009; 15(38): 4753-4762 - URL: https://www.wjgnet.com/1007-9327/full/v15/i38/4753.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.4753